Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is positioned for a successful entry into the market with its lead asset avutometinib showing strong efficacy in combination with defactinib in LGSOC, with potential to be the new standard of care for the indication that has 1,000-2,000 new patients per year. On top of this, the strong biological rationale behind the mechanism of action for avutometinib and its dual RAF/MEK inhibition, coupled with its potential for novel combination regimens, presents further upside for the stock, as demonstrated by the expected strong performance of KRAS G12D inhibitor VS-7375 and its peak sales projections of $292 million. Overall, the company faces the standard risks of the biopharmaceutical industry, but its promising pipeline and strong financials, including its preparation for self-sustaining revenue by 2H26, make it an attractive investment opportunity.

Bears say

Verastem is projected to have a slow and delayed market entry for its VS-7375 drug in the highly competitive space of 2L+ NSCLC and 2L+ PDAC treatment. Additionally, the projected partnership for EU commercialization may lead to a lower sales price for Verastem's drug in that region. Combined with a moderate probability of success and risk-adjusted peak sales, Verastem's financial outlook appears bleak with potentially limited revenue and profitability opportunities.

Verastem (VSTM) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.